Autoimmune Disease Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Immunosuppressant?s,Anti-Inflammatory Drugs,Corticosteroids,Nonsteroidal Anti-inflammatory Drugs,Biologics), By Application (Hospitals,Clinics,Drug Stores), Regional Insights and Forecast to 2035

Autoimmune Disease Treatment Market Overview

The global Autoimmune Disease Treatment Market size is projected to grow from USD 109866.92 million in 2026 to USD 112547.68 million in 2027, reaching USD 136515.51 million by 2035, expanding at a CAGR of 2.44% during the forecast period.

The Autoimmune Disease Treatment Market is expanding as global prevalence rises. Over 100 autoimmune conditions have been identified, affecting more than 350 million people worldwide in 2024. Autoimmune disorders account for 10% of the global healthcare burden, with rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus leading demand for therapies. Around 80% of autoimmune patients are women, representing a large treatment demographic. Biologics accounted for 38% of prescriptions, while conventional immunosuppressants and corticosteroids represented 42%, and NSAIDs and anti-inflammatory drugs covered the remaining 20%.

The United States accounts for 42% of the global autoimmune disease treatment market in 2024. An estimated 24 million Americans are diagnosed with autoimmune conditions, representing 7% of the U.S. population. Rheumatoid arthritis affects 1.3 million patients, multiple sclerosis impacts 1 million, and inflammatory bowel disease affects 3.1 million. Prescription biologics represented 41% of treatments, while corticosteroids covered 26%, immunosuppressants 18%, and NSAIDs 15%. U.S. hospitals dispensed more than 120 million autoimmune therapy prescriptions in 2024, supported by 6,000+ specialized clinics focusing on autoimmune disorders.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Biologics accounted for 38% of treatment share, with targeted therapies improving remission in 46% of patients.
• Major Market Restraint: High therapy costs affected 33% of patients, with 22% reporting treatment discontinuation.
• Emerging Trends: Personalized medicine adoption grew by 19% between 2022 and 2024, with 27% of therapies using genetic markers.
• Regional Leadership: North America led with 42% market share, followed by Europe with 28%, Asia-Pacific with 23%, and MEA at 7%.
• Competitive Landscape: Top 10 companies held 58% of prescriptions, with two firms controlling 23% combined share.
• Market Segmentation: Biologics captured 38% share, corticosteroids 26%, NSAIDs and anti-inflammatories together 20%, and immunosuppressants 16%.
• Recent Development: Biosimilar adoption rose by 32% in 2024, reducing biologic costs by 15% in select regions.

Autoimmune Disease Treatment Market Latest Trends

Autoimmune Disease Treatment Market Trends highlight the dominance of biologics and biosimilars. In 2024, biologics represented 38% of prescriptions, with over 12 million patients worldwide receiving these therapies. Biosimilars saw a 32% increase in adoption, accounting for 12% of biologic treatments. Immunosuppressants remained widely used, with 18% of patients prescribed them, primarily for organ-specific autoimmune disorders.

Combination therapy use rose, with 27% of patients receiving two or more drugs simultaneously. Digital health integration supported 15% of autoimmune patients with remote monitoring tools. Clinical trial activity surged, with more than 450 active autoimmune drug trials in 2024. Personalized medicine gained traction, with genetic biomarker-based prescriptions in 19% of cases. Regional disparities remained significant: North America accounted for 42% of treatments, while Asia-Pacific expanded to 23%, reflecting growing awareness and infrastructure.

Autoimmune Disease Treatment Market Dynamics

The Autoimmune Disease Treatment Market Dynamics describe the key forces that influence the growth and performance of the market, including drivers, restraints, opportunities, and challenges. Drivers include the rising prevalence of autoimmune diseases affecting more than 350 million people globally, and growing adoption of biologics which account for 38% of prescriptions. Restraints are shaped by high therapy costs, with 33% of patients reporting financial barriers and 22% discontinuing treatments. Opportunities are emerging in biosimilars and precision medicine, with biomarker-based therapies improving remission rates in 46% of patients. Challenges persist in the form of healthcare access gaps, where fewer than 40% of patients in low-income regions receive consistent care, and global workforce shortages, with fewer than 15,000 rheumatologists serving worldwide demand.

DRIVER

"Increasing prevalence of autoimmune disorders globally"

Autoimmune conditions affect more than 350 million people worldwide in 2024, with rheumatoid arthritis alone impacting 20 million patients globally. Inflammatory bowel disease cases reached 10 million, while multiple sclerosis affected 3 million. Women represent 80% of autoimmune patients, highlighting a gender-specific demand for treatments. Rising diagnosis rates, with autoimmune diseases growing by 4–7% annually, push continuous demand for immunosuppressants, biologics, and anti-inflammatory drugs.

RESTRAINT

"High treatment costs and limited affordability"

Around 33% of patients worldwide reported financial strain in accessing advanced biologics, while 22% discontinued treatments due to unaffordability. Biosimilars, though increasing adoption, still represent only 12% of biologic use, limiting broader accessibility. In developing regions, fewer than 35% of patients have consistent access to long-term therapies, constraining Autoimmune Disease Treatment Market Growth.

OPPORTUNITY

"Expansion of personalized and precision medicine"

By 2024, 19% of autoimmune treatments were guided by biomarker-based strategies. Genetic testing adoption grew to 21% in Europe and 17% in North America, supporting precision medicine. Tailored therapies improved remission rates in 46% of patients, presenting significant Autoimmune Disease Treatment Market Opportunities for pharma companies.

CHALLENGE

"Workforce shortages and treatment accessibility"

Globally, there are fewer than 15,000 rheumatologists for over 350 million patients, creating a major gap in specialized care. Wait times exceeded 6 months in many regions. Accessibility gaps persist, with 40% of patients in low-income areas lacking adequate autoimmune treatment options, constraining Autoimmune Disease Treatment Market Outlook.

Autoimmune Disease Treatment Market Segmentation

The Autoimmune Disease Treatment Market Segmentation divides the industry by type and application to better understand demand and adoption patterns. By type, biologics led with 38% share in 2024, followed by corticosteroids at 26%, immunosuppressants at 16%, and both NSAIDs and anti-inflammatory drugs at 10% each. By application, hospitals dispensed 55% of treatments, clinics accounted for 28%, and drug stores represented 17%, reflecting differences in accessibility, cost, and drug complexity.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Immunosuppressants: Immunosuppressants accounted for 16% of the global autoimmune disease treatment market in 2024, prescribed to more than 56 million patients worldwide. These therapies are primarily used in organ transplantation, autoimmune hepatitis, lupus nephritis, and severe rheumatoid arthritis cases. Around 44% of immunosuppressant demand is linked to transplant-related autoimmune conditions, while 38% is prescribed for chronic inflammatory diseases.

The Immunosuppressants segment is projected at USD 17,160.00 million in 2025, representing 16.00% of global share, and is expected to grow at a CAGR of 2.20% through 2034, driven by transplant-related and autoimmune disorder applications.

Top 5 Major Dominant Countries in the Immunosuppressants Segment

• United States: Market size USD 5,148.00 million in 2025, holding 30.00% share, with CAGR of 2.10%, supported by organ transplants and chronic autoimmune therapies.
• China: Market size USD 3,089.00 million in 2025, accounting for 18.00% share, with CAGR of 2.40%, fueled by rising diagnosis rates.
• Germany: Market size USD 1,717.00 million in 2025, capturing 10.00% share, with CAGR of 2.10%, focused on hospital-led treatments.
• India: Market size USD 1,544.00 million in 2025, equal to 9.00% share, with CAGR of 2.50%, boosted by affordability and generic production.
• France: Market size USD 1,200.00 million in 2025, comprising 7.00% share, with CAGR of 2.20%, linked to autoimmune hepatitis treatment.

Anti-Inflammatory Drugs: Anti-inflammatory drugs represented 10% of autoimmune disease treatment share in 2024, reaching over 35 million patients globally. These drugs are widely used for conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Around 52% of patients with early-stage autoimmune disorders are prescribed anti-inflammatory drugs as first-line treatments. Usage is highest in Asia-Pacific, which accounted for 38% of prescriptions, compared to 29% in North America and 25% in Europe.

The Anti-Inflammatory Drugs segment is valued at USD 10,725.00 million in 2025, holding 10.00% share, and will grow at a CAGR of 2.30% through 2034, supported by arthritis and bowel disease management.

Top 5 Major Dominant Countries in the Anti-Inflammatory Segment

• United States: Market size USD 3,217.00 million in 2025, with 30.00% share, CAGR of 2.20%, widely prescribed for arthritis.
• China: Market size USD 2,145.00 million in 2025, equal to 20.00% share, CAGR of 2.40%, driven by growing elderly population.
• Japan: Market size USD 1,072.00 million in 2025, 10.00% share, CAGR of 2.10%, supporting joint inflammation treatments.
• India: Market size USD 966.00 million in 2025, 9.00% share, CAGR of 2.50%, supported by generics expansion.
• Germany: Market size USD 858.00 million in 2025, 8.00% share, CAGR of 2.20%, focused on long-term arthritis care.

Corticosteroids: Corticosteroids accounted for 26% of the autoimmune disease treatment market share in 2024, prescribed to more than 90 million patients worldwide. These drugs are commonly used in systemic lupus erythematosus, multiple sclerosis flare-ups, and rheumatoid arthritis. Approximately 25% of autoimmune patients globally depend on long-term corticosteroid therapies, although 55% use them primarily during acute flare-ups. North America accounted for 34% of global corticosteroid use, while Europe contributed 30% and Asia-Pacific 28%.

The Corticosteroids segment is forecasted at USD 27,885.00 million in 2025, holding 26.00% global share, with a CAGR of 2.30% through 2034, extensively used for flare-up management.

Top 5 Major Dominant Countries in the Corticosteroids Segment

• United States: Market size USD 8,365.00 million in 2025, 30.00% share, CAGR of 2.20%, essential for lupus and arthritis.
• China: Market size USD 5,577.00 million in 2025, 20.00% share, CAGR of 2.40%, used in large-scale patient groups.
• Germany: Market size USD 2,231.00 million in 2025, 8.00% share, CAGR of 2.10%, widely applied for flare-up control.
• India: Market size USD 1,951.00 million in 2025, 7.00% share, CAGR of 2.50%, supported by affordability.
• France: Market size USD 1,672.00 million in 2025, 6.00% share, CAGR of 2.30%, for long-term autoimmune disease management.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs represented 10% of the autoimmune disease treatment market in 2024, serving approximately 36 million patients. These drugs are primarily used for pain and inflammation in conditions such as ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. Globally, NSAIDs accounted for 20% of prescriptions in hospitals, 55% in clinics, and 25% through drug stores, showing widespread accessibility.

The NSAIDs segment is anticipated at USD 10,725.00 million in 2025, contributing 10.00% share, and is projected to grow at a CAGR of 2.20% through 2034, mostly prescribed for pain and inflammation.

Top 5 Major Dominant Countries in the NSAIDs Segment

• United States: Market size USD 3,217.00 million in 2025, 30.00% share, CAGR of 2.10%, largest consumer of NSAIDs.
• China: Market size USD 2,145.00 million in 2025, 20.00% share, CAGR of 2.30%, rapidly growing patient base.
• India: Market size USD 1,287.00 million in 2025, 12.00% share, CAGR of 2.50%, widely available generics.
• Japan: Market size USD 1,072.00 million in 2025, 10.00% share, CAGR of 2.10%, adoption for arthritis cases.
• Germany: Market size USD 858.00 million in 2025, 8.00% share, CAGR of 2.20%, applied for inflammation control.

Biologics: Biologics dominated the Autoimmune Disease Treatment Market with 38% share in 2024, reaching more than 120 million patients globally. These therapies are especially effective for rheumatoid arthritis, psoriasis, Crohn’s disease, and multiple sclerosis. Biologics accounted for 41% of prescriptions in North America, 36% in Europe, and 33% in Asia-Pacific, with biosimilars representing 12% of global biologic use.

The Biologics segment dominates with USD 40,755.00 million in 2025, representing 38.00% share, and is expected to grow at a CAGR of 2.60% through 2034, driven by targeted therapies and biosimilars.

Top 5 Major Dominant Countries in the Biologics Segment

• United States: Market size USD 12,227.00 million in 2025, 30.00% share, CAGR of 2.50%, leading in targeted biologics.
• China: Market size USD 8,151.00 million in 2025, 20.00% share, CAGR of 2.70%, investing in biosimilar development.
• Germany: Market size USD 3,260.00 million in 2025, 8.00% share, CAGR of 2.30%, advanced biologic R&D.
• Japan: Market size USD 2,445.00 million in 2025, 6.00% share, CAGR of 2.20%, clinical adoption in arthritis and MS.
• India: Market size USD 2,038.00 million in 2025, 5.00% share, CAGR of 2.80%, rapid biosimilar growth.

BY APPLICATION

Hospitals: Hospitals represented the largest share of the Autoimmune Disease Treatment Market in 2024, accounting for 55% of total prescriptions, equivalent to more than 190 million treatments globally. Hospitals dominate biologics distribution, as 62% of biologics are administered via hospital infusion centers. North America led hospital-based treatments with 45% of global hospital prescriptions, followed by Europe with 32%, and Asia-Pacific with 18%.

Hospitals are projected at USD 58,987.51 million in 2025, representing 55.00% global share, growing at a CAGR of 2.40%, driven by biologics distribution and infusion therapy dominance.

Top 5 Major Dominant Countries in Hospital Applications

• United States: Market size USD 17,696.25 million in 2025, 30.00% share, CAGR of 2.30%, hospital-led biologics infusion.
• China: Market size USD 11,797.50 million in 2025, 20.00% share, CAGR of 2.50%, high hospital patient flow.
• Germany: Market size USD 4,719.00 million in 2025, 8.00% share, CAGR of 2.30%, advanced hospital care.
• India: Market size USD 4,129.00 million in 2025, 7.00% share, CAGR of 2.50%, expanding specialty hospitals.
• France: Market size USD 3,539.00 million in 2025, 6.00% share, CAGR of 2.30%, biologics adoption.

Clinics: Clinics accounted for 28% of the global autoimmune disease treatment market in 2024, dispensing more than 95 million prescriptions worldwide. Clinics play a major role in managing chronic care patients, particularly for conditions like rheumatoid arthritis, multiple sclerosis, and psoriasis. Around 38% of early-stage autoimmune treatments are initiated in clinics before hospital referrals. Regional adoption is highest in Europe, where clinics accounted for 35% of autoimmune prescriptions, compared to 28% in North America and 25% in Asia-Pacific.

Clinics will reach USD 30,030.00 million in 2025, holding 28.00% share, with CAGR of 2.40%, supporting chronic disease management and first-line therapies.

Top 5 Major Dominant Countries in Clinic Applications

• United States: Market size USD 9,009.00 million in 2025, 30.00% share, CAGR of 2.30%, extensive chronic care.
• China: Market size USD 6,006.00 million in 2025, 20.00% share, CAGR of 2.50%, growing specialty clinics.
• Germany: Market size USD 2,402.00 million in 2025, 8.00% share, CAGR of 2.20%, strong outpatient care.
• India: Market size USD 2,102.00 million in 2025, 7.00% share, CAGR of 2.60%, increased access in tier-2 cities.
• UK: Market size USD 1,801.00 million in 2025, 6.00% share, CAGR of 2.20%, specialist clinics expansion.

Drug Stores: Drug stores contributed 17% of autoimmune disease treatment distribution in 2024, equivalent to 60 million prescriptions worldwide. They primarily distribute corticosteroids, NSAIDs, and generic immunosuppressants, which together account for 65% of drug store prescriptions. Over-the-counter NSAIDs represented 40% of drug store sales, supporting 36 million patients globally. North America dominated with 44% of global drug store prescriptions, followed by Asia-Pacific with 31%, and Europe with 22%.

Drug stores are expected at USD 18,232.51 million in 2025, accounting for 17.00% of global share, with a CAGR of 2.30%, mainly dispensing corticosteroids, NSAIDs, and generics.

Top 5 Major Dominant Countries in Drug Store Applications

• United States: Market size USD 5,469.75 million in 2025, 30.00% share, CAGR of 2.20%, leading generic distribution.
• China: Market size USD 3,646.50 million in 2025, 20.00% share, CAGR of 2.40%, growing accessibility.
• India: Market size USD 1,822.00 million in 2025, 10.00% share, CAGR of 2.50%, strong generics presence.
• Germany: Market size USD 1,458.00 million in 2025, 8.00% share, CAGR of 2.20%, stable OTC sales.
• Japan: Market size USD 1,277.00 million in 2025, 7.00% share, CAGR of 2.10%, pharmacy-based access.

Regional Outlook for the Autoimmune Disease Treatment Market

The Regional Outlook for the Autoimmune Disease Treatment Market provides a geographic analysis of how demand, market size, share, and growth trends are distributed across different regions. It highlights variations in patient populations, therapy adoption, healthcare infrastructure, and accessibility across North America, Europe, Asia, and the Middle East & Africa.

In 2025, the market is valued at USD 107,250.02 million globally, with North America holding 42% share, Europe 28%, Asia 23%, and Middle East & Africa 7%, reflecting differences in treatment adoption, biosimilar penetration, and hospital-based care.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominated the Autoimmune Disease Treatment Market with 42% global share in 2024, supported by advanced healthcare infrastructure, high biologics adoption, and strong clinical research activity. The United States accounted for 85% of regional demand, with more than 24 million patients diagnosed with autoimmune disorders such as rheumatoid arthritis (1.3 million cases), multiple sclerosis (1 million cases), and inflammatory bowel disease (3.1 million cases). Canada contributed 9% of the regional market, while Mexico held 6%, both showing rising biosimilar uptake.

North America Autoimmune Disease Treatment Market size is USD 45,045.01 million in 2025, representing 42.00% share, growing at a CAGR of 2.30%, led by the U.S. with advanced biologics adoption.

North America - Major Dominant Countries in the “Autoimmune Disease Treatment Market”

• United States: Market size USD 38,288.00 million in 2025, 85.00% share, CAGR of 2.30%, strong biologics and biosimilars demand.
• Canada: Market size USD 4,054.00 million in 2025, 9.00% share, CAGR of 2.20%, growing biologics.
• Mexico: Market size USD 2,703.00 million in 2025, 6.00% share, CAGR of 2.40%, generic adoption.
• Brazil (regional overlap): Market size USD 1,351.00 million, 3.00% share, CAGR of 2.20%, increasing adoption.
• Chile: Market size USD 648.00 million, 1.50% share, CAGR of 2.10%, developing access.

EUROPE

Europe held 28% of the global autoimmune disease treatment market share in 2024, with more than 90 million patients affected by autoimmune disorders. Germany, France, and the UK collectively accounted for 65% of European demand, with Germany leading at 12 million patients and biologics adoption at 39% of prescriptions. France had over 10 million cases, while the UK had nearly 8 million patients under autoimmune care. Biosimilar adoption grew by 32% across Europe, helping reduce therapy costs by an average of 15% in 2024. Corticosteroids represented 25% of prescriptions, while immunosuppressants were prescribed to 20% of patients.

The Europe Autoimmune Disease Treatment Market is estimated at USD 30,030.00 million in 2025, accounting for 28.00% of global share, with a CAGR of 2.30% through 2034. Europe’s strength lies in biosimilar adoption, advanced hospital networks, and national healthcare systems that enhance accessibility for over 90 million autoimmune patients.

Europe - Major Dominant Countries in the “Autoimmune Disease Treatment Market”

• Germany: Market size USD 9,009.00 million in 2025, 30.00% regional share, CAGR of 2.20%, driven by biologics and biosimilars adoption.
• France: Market size USD 7,507.00 million in 2025, 25.00% share, CAGR of 2.30%, with strong corticosteroid use.
• United Kingdom: Market size USD 6,006.00 million in 2025, 20.00% share, CAGR of 2.20%, supported by NHS coverage for biologics.
• Italy: Market size USD 3,003.00 million in 2025, 10.00% share, CAGR of 2.10%, significant hospital-based prescriptions.
• Spain: Market size USD 1,502.00 million in 2025, 5.00% share, CAGR of 2.20%, rising biosimilar demand.

ASIA-PACIFIC

Asia-Pacific captured 23% of the autoimmune disease treatment market in 2024, representing over 110 million patients. China accounted for 45% of regional demand, India 28%, and Japan 18%, while South Korea and Australia shared the remaining 9%. China’s patient base exceeded 50 million individuals, with 15 million rheumatoid arthritis cases and 4 million multiple sclerosis patients. India reported 31 million cases, with rising demand for corticosteroids and cost-effective biosimilars. Japan had over 20 million patients, with biologics adoption reaching 33% of prescriptions. 

The Asia Autoimmune Disease Treatment Market is valued at USD 24,667.00 million in 2025, representing 23.00% of global share, with a CAGR of 2.50%, supported by a massive patient pool exceeding 110 million individuals. Asia’s growth is driven by biosimilars, generic corticosteroids, and hospital expansion in major economies.

Asia - Major Dominant Countries in the “Autoimmune Disease Treatment Market”

• China: Market size USD 11,100.00 million in 2025, 45.00% share, CAGR of 2.60%, strong biologics and biosimilars production.
• India: Market size USD 6,907.00 million in 2025, 28.00% share, CAGR of 2.70%, fueled by generics and affordability.
• Japan: Market size USD 4,440.00 million in 2025, 18.00% share, CAGR of 2.20%, advanced biologics adoption.
• South Korea: Market size USD 1,110.00 million in 2025, 5.00% share, CAGR of 2.40%, increasing autoimmune therapies.
• Australia: Market size USD 740.00 million in 2025, 3.00% share, CAGR of 2.30%, with widespread access through public healthcare.

MIDDLE EAST & AFRICA

The Middle East & Africa (MEA) represented 7% of the global autoimmune disease treatment market in 2024, serving around 20 million patients. The UAE contributed 28% of regional demand, Saudi Arabia 25%, and South Africa 18%, while Egypt and Nigeria together accounted for 15%. Autoimmune conditions in MEA included 4 million rheumatoid arthritis cases, 2 million multiple sclerosis patients, and 1.5 million inflammatory bowel disease cases. However, fewer than 40% of patients received consistent therapies, with biologics adoption limited to 18% of prescriptions, compared to 41% in North America. 

The Middle East & Africa Autoimmune Disease Treatment Market is projected at USD 7,507.00 million in 2025, making up 7.00% global share, with CAGR of 2.10%. MEA’s market is driven by Saudi Arabia, UAE, and South Africa, though treatment accessibility remains below 40% across rural areas.

Middle East and Africa - Major Dominant Countries in the “Autoimmune Disease Treatment Market”

• United Arab Emirates: Market size USD 2,252.00 million in 2025, 30.00% regional share, CAGR of 2.20%, investing in biologics imports.
• Saudi Arabia: Market size USD 1,877.00 million in 2025, 25.00% share, CAGR of 2.10%, focused on defense-driven healthcare systems.
• South Africa: Market size USD 1,351.00 million in 2025, 18.00% share, CAGR of 2.00%, expanding clinical infrastructure.
• Egypt: Market size USD 900.00 million in 2025, 12.00% share, CAGR of 2.00%, dominated by corticosteroids and NSAIDs.
• Nigeria: Market size USD 525.00 million in 2025, 7.00% share, CAGR of 2.10%, emerging as a generics hub.

List of Top Autoimmune Disease Treatment Companies

• Active Biotech
• Lupin Limited
• Pfizer
• Biogen Idec
• Abbott Laboratories
• Amgen
• 4SC AG
• Eli Lilly
• GlaxoSmithKline
• Hoffmann-La Roche Ltd.
• Johnson & Johnson
• AstraZeneca plc
• AutoImmune Inc
• Bristol-Myers Squibb
• Bayer

Pfizer: Accounted for 12% of global prescriptions in 2024, with strong biologics and biosimilar portfolio.

Johnson & Johnson: Held 11% of prescriptions, particularly dominant in biologics for rheumatoid arthritis and Crohn’s disease.

Investment Analysis and Opportunities

Investments in autoimmune disease treatment exceeded 450 active clinical trials in 2024, with 60% focused on biologics and biosimilars. Around 25% of funding went into precision medicine and genetic biomarker development. North America accounted for 48% of global R&D investment, followed by Europe at 28%. Asia-Pacific, representing 18% of investment, prioritized affordable biosimilar programs.

Hospitals and specialized clinics accounted for 55% of funding allocation, while 20% of investment targeted digital health platforms. Opportunities lie in biologics expansion, with global adoption rising by 12% year-on-year, and biosimilars that cut treatment costs by 15%, enabling access to an additional 20 million patients worldwide.

New Product Development

More than 120 new autoimmune therapies were introduced between 2023 and 2025. Biologics accounted for 38%, biosimilars 18%, and oral immunotherapies 12%. Targeted JAK inhibitors were prescribed to 8% of autoimmune patients globally.

Digital therapeutics supported 15% of patients with app-based monitoring, while infusion innovations improved biologic delivery for 25% of users. Over 450 clinical trials are ongoing, with 30% in Phase III. The focus remains on improving remission rates, which currently average 46% under combination therapies, and reducing flare-ups that affect 70% of patients within five years of diagnosis.

Five Recent Developments

• Launch of over 30 biosimilars covering rheumatoid arthritis and Crohn’s disease.
• JAK inhibitors reached 8% prescription share globally.
• Digital health adoption rose to 15% of patients, enhancing treatment monitoring.
• Biosimilar adoption reduced biologic therapy costs by 15% worldwide.
• Over 450 autoimmune clinical trials active, with 30% at Phase III stage.

Report Coverage of Autoimmune Disease Treatment Market

The Autoimmune Disease Treatment Market Research Report covers market segmentation by type, application, and region. Biologics accounted for 38% share, corticosteroids 26%, immunosuppressants 16%, and NSAIDs/anti-inflammatory drugs 20% in 2024. Hospitals dispensed 55% of prescriptions, clinics 28%, and drug stores 17%.

Regionally, North America led with 42% share, Europe held 28%, Asia-Pacific 23%, and Middle East & Africa 7%. Top 10 companies controlled 58% of treatments, with Pfizer and Johnson & Johnson together holding 23% combined share. With over 350 million patients worldwide, the report provides Autoimmune Disease Treatment Market Insights, Autoimmune Disease Treatment Market Forecast, and Autoimmune Disease Treatment Industry Analysis for stakeholders, identifying key Autoimmune Disease Treatment Market Opportunities in biologics, biosimilars, and precision medicine.

Autoimmune Disease Treatment Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 109866.92 Million in 2026
Market Size Value By	USD 136515.51 Million by 2035
Growth Rate	CAGR of 2.44% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Immunosuppressant?s Anti-Inflammatory Drugs Corticosteroids Nonsteroidal Anti-inflammatory Drugs Biologics By Application : Hospitals Clinics Drug Stores
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample